265 related articles for article (PubMed ID: 30701564)
1. Is EGFR really a therapeutic target in head and neck cancers?
Agarwal V; Subash A; Nayar RC; Rao V
J Surg Oncol; 2019 May; 119(6):685-686. PubMed ID: 30701564
[TBL] [Abstract][Full Text] [Related]
2. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Agulnik M
Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
[TBL] [Abstract][Full Text] [Related]
3. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
4. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Zibelman M; Mehra R
Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
[TBL] [Abstract][Full Text] [Related]
5. Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.
Iberri DJ; Colevas AD
Oncologist; 2015 Dec; 20(12):1393-403. PubMed ID: 26446236
[TBL] [Abstract][Full Text] [Related]
6. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
8. EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Loeffler-Ragg J; Schwentner I; Sprinzl GM; Zwierzina H
Expert Opin Investig Drugs; 2008 Oct; 17(10):1517-31. PubMed ID: 18808311
[TBL] [Abstract][Full Text] [Related]
9. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Brockstein B; Lacouture M; Agulnik M
J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
[TBL] [Abstract][Full Text] [Related]
10. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
11. EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer.
Ma W; Concha-Benavente F; Santegoets SJAM; Welters MJP; Ehsan I; Ferris RL; van der Burg SH
PLoS One; 2018; 13(9):e0203402. PubMed ID: 30192802
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.
Reuter CW; Morgan MA; Eckardt A
Br J Cancer; 2007 Feb; 96(3):408-16. PubMed ID: 17224925
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
15. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
16. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
[TBL] [Abstract][Full Text] [Related]
17. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
Caponigro F
Anticancer Drugs; 2004 Apr; 15(4):311-20. PubMed ID: 15057134
[TBL] [Abstract][Full Text] [Related]
18. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
19. Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance.
Saba NF; Chen ZG; Haigentz M; Bossi P; Rinaldo A; Rodrigo JP; Mäkitie AA; Takes RP; Strojan P; Vermorken JB; Ferlito A
Mol Cancer Ther; 2019 Nov; 18(11):1909-1915. PubMed ID: 31676542
[TBL] [Abstract][Full Text] [Related]
20. Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
Zhao Y; Liu W; Sun M; Miao Q; Liu Y; Tian H; Su Y; Han F
Crit Rev Oncol Hematol; 2019 Mar; 135():39-46. PubMed ID: 30819445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
